A Study of the Efficacy and Safety of Danicamtiv in Participants With Symptomatic Genetic and Familial Dilated Cardiomyopathy
A legfontosabb adatok
- Ki végzi
- Kardigan, Inc.
- Hol
- Bari, Florence, Milan, Padova, Pavia, Roma, Rozzano és Trieste (Olaszország)Mind a 10 helyszín megnézéseMég 10 másik országban, 69 helyszínen
- Azonosító
- Állapot
- Toboroz
- Fázis
- 2/3. fázis
- Résztvevők
- 332 fő, tervezett
- Kezdés
- 2026. febr. 13.
- Várható befejezés
- 2028. jan.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoportAz egyik csoport placebót (hatóanyag nélküli szert) kap, összehasonlításként.
- A vizsgált kezelések
- danicamtiv
- Placebo
- A regiszteradat frissítve
- 2026. november 4.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
The trial is looking for adults with genetic or familial dilated cardiomyopathy (a weak, enlarged heart muscle) who have symptoms. It compares danicamtiv with a placebo.
- Életkor
- 18 Years and older
- Nem
- All sexes can join
- A betegség stádiuma
- NYHA Class II-IV heart failure, with symptoms stable for ≥1 month. At least mild enlargement of the left heart chamber. LVEF (pumping strength) of ≤45%. Peak oxygen uptake in an exercise test of 80% or less of that predicted for a healthy person.
- Korábbi kezelés
- Must be on stable doses of standard heart failure medicines, at the highest dose tolerated, for at least 4 weeks before the first visit.
- Biomarker vagy leletérték
- A probable disease-causing change in MYH7, TTN or another known DCM gene, or DCM that runs in the family.
A részvétel fő kizáró okai
- Heart failure caused mainly by blocked heart arteries, valve disease or another condition, or DCM from substance abuse, amyloidosis or sarcoidosis
- A serious heart event or heart failure hospital stay in the last 90 days
- Irregular heart rhythms that disturb heart scans, or unstable or untreated severe ventricular arrhythmia
- Cancer of any type within 5 years
- Past heart transplant or one expected within 6 months, or severe kidney failure (eGFR <15 mL/min/1.73m2)
A regiszter feltételei, szó szerint
Mind a 17 feltétel megnézéseKevesebb
Ki vehet részt
- Has a diagnosis of DCM due to probable disease-causing variants of MYH7, TTN, or other identified genetic DCM variants, or with familial DCM
- Has New York Heart Association (NYHA) Class II-IV at Screening with stable symptoms for ≥1 month
- Has at least mild left ventricular enlargement (LVE) and has adequate acoustic windows to enable accurate TTEs according to the Echocardiography Core Laboratory
- Has a LVEF of ≤45%
- Is on stable doses of maximally tolerated standard-of-care heart failure (HF) therapies reflecting current guidelines for at least 4 weeks prior to the first visit
- Has DCM not attributed to substance abuse, amyloidosis, sarcoidosis, or any other secondary form of cardiomyopathy per the Investigator
- Can perform an upright cardiopulmonary exercise training (CPET) with a peak oxygen uptake (pV̇O2) of 80% or less of predicted for a healthy individual and respiratory exchange ratio (RER) of ≥1.05
Ki nem vehet részt
- Has heart failure with reduced ejection (HFrEF) caused primarily by ischemic heart disease, chronic valvulopathy, or another condition, as determined by the Investigator
- Recent (<90 days) clinically significant cardiac events, including acute coronary syndrome, hemodynamically significant epicardial coronary disease (per Investigator), coronary revascularization (percutaneous coronary intervention [PCI] or coronary artery bypass graft [CABG]), or hospitalization for heart failure/intravenous (IV) diuretic use
- Presence of disqualifying cardiac rhythms that might interfere with reliable echocardiographic measurements of left ventricle (LV) function, as determined by the Investigator including: (a) inadequately rate-controlled atrial fibrillation, (b) ectopic beats (atrial, junctional or ventricular) of sufficient frequency (e.g. > 10% of total beats) that the participant's cardiac rhythm is irregular potentially interfering with reliable echocardiographic measurements of LV function
- History of malignancy of any type within 5 years prior to Screening
- History or evidence of any other clinically significant disorder, condition, or disease that, in the opinion of the Investigator or Sponsor, would pose a risk to participant safety or interfere with the study evaluation
- History of heart transplantation or anticipated heart transplantation in the next 6 months
- Ongoing or anticipated advanced cardiac interventions, including chronic IV inotropic therapy, planned cardiac resynchronization therapy (CRT) or major surgery, or current/anticipated ventricular assist device placement within 6 months
- Severe renal insufficiency (defined at the time of Screening as current estimated glomerular filtration rate [eGFR] <15 mL/min/1.73m2 by simplified Modification of Diet in Renal Disease equation [sMDRD])
- Clinically significant laboratory abnormalities at Screening
- Unstable or untreated severe ventricular arrythmia (eg, ventricular tachycardia or ventricular fibrillation)
Helyszínek itt: Olaszország
Még 10 másik országban, 69 helyszínen
- Azienda Ospedaliera Universitaria Consorziale - Policlinico BariBari, OlaszországContact: Kardigan Clinical Trial TeamRésztvevőt keres
- Azienda Ospedaliero-Universitaria CareggiFlorence, OlaszországContact: Kardigan Clinical Trial TeamRésztvevőt keres
- ASST Grande Ospedale Metropolitano NiguardaMilan, OlaszországContact: Kardigan Clinical Trial TeamRésztvevőt keres
- Centro Cardiologico MonzinoMilan, OlaszországContact: Kardigan Clinical Trial TeamRésztvevőt keres
- IRCCS Ospedale San RaffaeleMilan, OlaszországContact: Kardigan Clinical Trial TeamToborzás még nem indult
- Azienda Ospedale Universita PadovaPadova, OlaszországContact: Kardigan Clinical Trial TeamToborzás még nem indult
- Fondazione IRCCS Policlinico San MatteoPavia, OlaszországContact: Kardigan Clinical Trial TeamToborzás még nem indult
- Ospedale Policlinico CasilinoRoma, OlaszországContact: Kardigan Clinical Trial TeamToborzás még nem indult
- Istituto Clinico HumanitasRozzano, OlaszországContact: Kardigan Clinical Trial TeamRésztvevőt keres
- Azienda sanitaria universitaria Giuliano Isontina (ASU GI) - Ospedale di CattinaraTrieste, OlaszországContact: Kardigan Clinical Trial TeamRésztvevőt keres
A vizsgálatról
Mit akar kideríteni a vizsgálat
The Sponsor is studying an investigational medication called danicamtiv to determine if it can help people with genetic and familial dilated cardiomyopathy (DCM). Investigational means that the safety and effectiveness of danicamtiv have not been established. Currently, there are no approved drugs that are designed specifically to treat genetic or familial DCM.
A teljes eredeti leírásKevesebb
The purpose of this study is to evaluate how well danicamtiv works compared to a placebo (sugar pill that looks like danicamtiv pill but does not contain any danicamtiv) and see how safe it is for people with genetic and familial DCM. In DCM, the heart muscle weakens and enlarges, making it harder for the heart to pump blood; this can happen for different reasons. Some people have DCM because of a change in a gene (called genetic DCM). Others may have DCM that runs in their family, even if no specific gene change is found (called familial DCM).
The main goals of the study are:
* To assess the effect of danicamtiv on cardiac function using echocardiogram. * To evaluate the impact of danicamtiv on exercise capacity * To evaluate the safety and tolerability of danicamtiv
Participants will:
* Take danicamtiv or placebo every day for approximately 6 months * Visit the clinic about 12 times for initial evaluation, checkups, tests and follow up
A vizsgálat 2 csoportja
- danicamtivA vizsgált kezelés
- placeboPlacebo, összehasonlításként
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- A Phase 2b/3, Adaptive, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Danicamtiv in Participants With Symptomatic Genetic and Familial Dilated Cardiomyopathy
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
- A regiszteradat frissítve
- 2026. november 4.